BJDX
Bluejay Diagnostics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
MACD Golden Cross
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BJDX
Bluejay Diagnostics, Inc.
A medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression
Healthcare Equipment and Supplies
03/20/2015
11/10/2021
NASDAQ Stock Exchange
7
12-31
Common stock
360 Massachusetts Avenue, Suite 203, Acton, MA 01720
--
Bluejay Diagnostics, Inc., was incorporated under the laws of the State of Delaware on March 20, 2015. The company is a medical diagnostic company focused on classifying, diagnosing and monitoring disease progression through products that are more cost-effective, fast and close to patients, thereby improving patient outcomes. The company believes that the market needs on-site rapid diagnostic systems that can be used for testing and monitoring. The company's diagnostic system, called Symphony, is an exclusively licensed, patented, low-cost system consisting of a small footprint instrument and a one-time specific instruction test box.
Company Financials
EPS
BJDX has released its 2025 Q3 earnings. EPS was reported at -1.01, versus the expected 0, missing expectations. The chart below visualizes how BJDX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
